Piribo: Novartis, New Publication Announcement
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Novartis - Prospects to 2010”. http://www. piribo. com/publications/pharmaceutical_companies/novartis/novartis. html
(PRWEB) August 31, 2006
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Novartis - Prospects to 2010”.
Novartis was created in 1996 from the merger of the Swiss companies, Ciba and Sandoz. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.
Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field. Novartis is currently organised into the three divisions of Pharmaceuticals, Consumer Health and Sandoz. A fourth division, Vaccines & Diagnostics, will be created after the acquisition of Chiron Corporation.
Current Growth Drivers
These include: Diovan (valsartan), Glivec/Gleevec (imatinib), Zelmac/Zelnorm (tegaserod), Femara (letrozole) and Zometa (zoledronate).
Key Late-Phase Products Reaching the Market
Lucentis (ranibizumab) is currently filed for age-related macular degeneration.
Two cardiovascular products currently filed have the potential to become mega-blockbusters: Rasilez (aliskiren) for the treatment of hypertension; and Galvus (vildagliptin), indicated for Type II diabetes.
Key Late-Stage Products
Fingolimod is under Phase III development for multiple sclerosis.
Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Contents
Executive Summary
Product Portfolio / Research & Development
Appendix 1 - Financial Performance
Appendix 2 - Key Agree Ments
Esbatech Ag
Appendix 3 - Infrastructure
Appendix 4 - Key Pharmaceutical
Subsidiaries / Joint Ventures
“Novartis - Prospects to 2010” is available from Piribo. For more information go to: http://www. piribo. com/publications/pharmaceutical_companies/novartis/novartis. html (http://www. piribo. com/publications/pharmaceutical_companies/novartis/novartis. html)
Piribo Product ID: ESP962
About Piribo:
Piribo (http://www. piribo. com (http://www. piribo. com)) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.
###
